Pharm Sci Advisory Committee Revisiting Controversial Topics
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Pharmaceutical Science and Clinical Pharmacology expert panel will try to make strides in the regulatory minefields of bioequivalence and transdermal drug delivery systems.